6 recruiting, 2 not yet recruiting, 2 withdrawn. 3 Phase 2, 3 Phase 3, 2 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 2 | Recruiting 1, Withdrawn 1 |
| Not applicable | 1 | Withdrawn 1 |
Follow Early Stage Triple-Negative Breast Carcinoma: new trials by email Literature Review of Early Stage Triple-Negative Breast Carcinoma trials Research Report on Early Stage Triple-Negative Breast Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer Live biotherapeutic product: MO-03 1 capsule PO BID - TNBC - Triple-Negative Breast Cancer, TNBC | Phase 2 | Not yet recruiting | Yuan Yuan | 50 | 2026-09-01 | 2026-08-05 |
| Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy Standard of care plus pembrolizumab, Standard of care (capecitabine or olaparib) - Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Not yet recruiting | The Netherlands Cancer Institute | 1000 | 2026-04-01 | 2026-03-20 |
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial Biospecimen Collection, Hormone Therapy, Pembrolizumab - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 120 | 2025-10-09 | 2026-11-03 |
| Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer Ivonescimab, Carboplatin, Docetaxel - TNBC, TNBC - Triple-Negative Breast Cancer | Phase 2 | Recruiting | Cedars-Sinai Medical Center | 34 | 2025-07-25 | 2026-08-04 |
| TNBC Gut Microbiota During Neoadjuvant Treatment Nutritional Counseling - Breast Cancer, Triple Negative Breast Cancer | Not applicable | Withdrawn | Scripps Health | 2025-04-10 | 2026-08-12 | |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer Biospecimen Collection, Carboplatin, Cyclophosphamide - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 3 | Recruiting | SWOG Cancer Research Network | 2400 | 2023-09-15 | 2025-11-05 |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab Pembrolizumab, Patient Observation, Biopsy - Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1295 | 2023-06-14 | 2026-08-05 |
| Implantable Microdevice for TNBC - Pilot Study Implantable Microdevice (IMD) - Triple Negative Breast Cancer, Breast Cancer Stage II | Phase 1 | Withdrawn | Dana-Farber Cancer Institute | 2023-05-01 | 2023-05-18 |
Triple Negative Breast Neoplasms (6) · Breast Neoplasms (4) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinosarcoma (1) · Clear-cell metastatic renal cell carcinoma (1) · Colorectal Neoplasms (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Neoplasm Metastasis (1) · Skin Neoplasms (1) · Uterine Cervical Neoplasms (1)
Neoplasms (7) · Neoplasms by Site (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7) · Breast Diseases (6) · Breast Neoplasms (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Female Urogenital Diseases (1)
pembrolizumab (5) · Specimen Handling (3) · Carboplatin (2) · Docetaxel (2) · 2C4 antibody (1) · Biopsy (1) · Blood Specimen Collection (1) · CT-P6 (1) · CTLA-4 Antigen (1) · Capecitabine (1) · Cyclophosphamide (1) · Doxorubicin (1) · Hormones (1) · Immunotherapy, Active (1) · Ipilimumab (1)
Alliance for Clinical Trials in Oncology (1) · Cedars-Sinai Medical Center (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · SWOG Cancer Research Network (1) · Scripps Health (1) · The Netherlands Cancer Institute (1) · Yuan Yuan (1)
United States (8) · Puerto Rico (2) · Canada (1) · Mexico (1)
Yuan Yuan, MD (2) · Agnes Jager, MD, PhD (1) · Ana Garrido-Castro, MD (1) · Dev Mukhopadhyay, PhD (1) · Gabe Sonke, MD, PhD (1) · Jin Sun Lee-Bitar, MD (1) · Keerthi Gogineni, MD, MSHP (1) · Lee Hong, MD, PhD (1) · Marleen Kok, MD, PhD (1) · Priyanka Sharma (1) · Vicente Valero, MD (1)
PMID 40791544, PMID 41213254, PMID 41484629
2025 (1), P30CA016672 (1), P30CA138292 (1), R44CA257278 (1), U10CA180888 (1)